Evaluating a Dropless Postoperative Regimen After Cataract Surgery in a Vulnerable, County-hospital Population
Launched by UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · Nov 30, 2021
Trial Information
Current as of June 01, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at a new way to care for patients after cataract surgery at Zuckerberg San Francisco General Hospital. Currently, patients must use multiple eye drops after their surgery, which can be difficult to manage and lead to complications if they forget or struggle to use them. The researchers want to see if giving patients one single injection of medication during surgery, instead of several eye drops afterward, can improve recovery and make it easier for patients to follow their treatment plan.
To be part of this study, you need to be at least 18 years old and have been approved for cataract surgery in both eyes. However, if you have certain eye conditions, allergies to specific medications, or are pregnant or breastfeeding, you won't be eligible. If you choose to participate, you'll receive the new treatment during your surgery and the team will follow up to see how well you recover and how satisfied you are with the care you received. This study aims to make postoperative care simpler and more effective for patients in need.
Gender
ALL
Eligibility criteria
- Inclusion criteria:
- • ZSFG patient initially seen in the eye clinic, approved by attending ophthalmologist for cataract surgery in both eyes due to visually significant cataracts, and who elects to have cataract surgery in both eyes.
- • Patients 18 years of age or older
- Exclusion criteria:
- • Patients requiring bilateral simultaneous (same-day bilateral) cataract surgery
- • Patients with prior history of: endophthalmitis, advanced glaucoma, known history of intraocular pressure elevation due to steroids, prior intraocular surgery, cystoid macular edema/diabetic macular edema/retinal edema noted in the past 12 months prior to cataract surgery
- • Patients with documented penicillin or cephalosporin allergy or intolerance
- • Patients requiring combined same day cataract and ophthalmic subspecialty procedure (eg; combined cataract and glaucoma, retina, or cornea surgery).
- • Patients who are pregnant or breastfeeding
About University Of California, San Francisco
The University of California, San Francisco (UCSF) is a leading academic institution renowned for its commitment to advancing healthcare through innovative research and clinical trials. With a focus on translating scientific discoveries into effective therapies, UCSF collaborates with a diverse array of stakeholders, including healthcare professionals, industry partners, and patient communities. The university's research programs emphasize interdisciplinary approaches and leverage cutting-edge technology to address complex medical challenges. As a sponsor of clinical trials, UCSF is dedicated to maintaining the highest standards of ethical conduct and scientific rigor, ensuring the safety and well-being of participants while contributing to the broader medical knowledge base.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
San Francisco, California, United States
Patients applied
Trial Officials
Sriranjani P Padmanabhan, MD
Principal Investigator
University of California, San Francisco
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials